Aqneursa Granule, For Suspension
FDA Label NDC 83853-101

26 label sections · Submitted to the FDA by Intrabio Inc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Intrabio Inc for the product Aqneursa (NDC 83853-101). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 niemann-pick disease type c, 1.2 ataxia-telangiectasia, 2.1 important recommendation prior to aqneursa treatment initiation, 2.2 recommended dosage, 2.3 preparation and administration instructions, 3 dosage forms and strengths, 4 contraindications, 5.1 embryo-fetal toxicity, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

1.1 Niemann-Pick Disease Type C

AQNEURSA® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.

1.2 Ataxia-Telangiectasia

AQNEURSA is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Niemann-Pick Disease Type C

The safety of AQNEURSA was evaluated in Trial 1, which included a total of 60 patients with Niemann-Pick disease Type C (NPC), in a placebo-controlled, randomized, crossover trial [see Clinical Studies (14.1)]. The mean (SD) treatment duration of AQNEURSA was 86.2 (4.7) days (69 min, 97 max); the mean (SD) treatment duration on placebo was 87.3 (4.8) days (78 min, 113 max).

Table 2 summarizes adverse reactions that occurred in patients who were treated with AQNEURSA in Treatment Period I of Trial 1.

Table 2: Adverse Reactions that Occurred in Adult and Pediatric Patients with NPC at an Incidence of ≥5% in Treatment Period I of Trial 1

Adverse Reaction

AQNEURSA
N=30
n (%)

Placebo
N=30
n (%)

Upper respiratory tract infection

5 (17)

1 (3)

Abdominal pain

2 (7)

0 (0)

Dysphagia

2 (7)

0 (0)

Vomiting

2 (7)

0 (0)

Rosacea

One patient experienced an exacerbation of rosacea during Trial 1 that responded to treatment. AQNEURSA was not discontinued.

Laboratory Findings

Thrombocytopenia with platelets < 100 10^3 cells/µL was observed in four patients during Treatment Period 1 of Trial 1, all of whom were receiving miglustat for 42 days or longer at the time of enrollment. In two of these patients, the thrombocytopenia was present at baseline. In the other two patients, the thrombocytopenia developed during Trial 1.

Ataxia-Telangiectasia

The safety of AQNEURSA was evaluated in Trial 2, which included a total of 73 patients with ataxia-telangiectasia (A-T) in a placebo-controlled, randomized, crossover trial [see Clinical Studies (14.2)]. The mean (SD) treatment duration of AQNEURSA was 84.5 (11.2) days (9 min, 97 max); the mean (SD) treatment duration on placebo was 85.5 (3.6) days (77 min, 94 max).

Table 3 summarizes common adverse reactions that occurred in patients who were treated with AQNEURSA in Treatment Period I of Trial 2.

Table 3: Adverse Reactions that Occurred in Adult and Pediatric Patients with A-T at an Incidence of ≥5% in Treatment Period I of Trial 2

Adverse Reaction

AQNEURSA
N=36
n (%)

Placebo
N=37
n (%)

Fall

2 (6)

1 (3)

Skin laceration

2 (6)

0 (0)

Urinary tract infection

2 (6)

1(3)

Laboratory Findings

Thrombocytopenia with platelets < 100 10^3 cells/µL was observed in one patient during Trial 2. The patient had thrombocytopenia at baseline, which decreased further during the trial while the patient was receiving placebo.

14.1 Niemann-Pick Disease Type C

The safety and efficacy of AQNEURSA for the treatment of NPC were evaluated in a randomized, double-blind, placebo-controlled, two-period crossover study that evaluated the efficacy of AQNEURSA in 60 patients (Trial 1, NCT05163288). To be eligible for the study, patients had to be aged 4 years or older with a confirmed diagnosis of NPC. Patients were required to have at least mild disease-related neurological symptoms.

Patients were assessed over a 2-week baseline period. Patients were then randomized in a 1:1 ratio to one of the two treatment sequences:

  • Treatment Sequence 1 (N=30): AQNEURSA in Treatment Period I, followed by immediate crossover to placebo in Treatment Period II
  • Treatment Sequence 2 (N=30): placebo in Treatment Period I, followed by immediate crossover to AQNEURSA in Treatment Period II.
  • AQNEURSA and placebo were administered orally with or without food for 12 weeks in each period.

    Patients aged ≥13 years received 4 gram per day (as 2 gram morning dose, 1 gram afternoon dose, and 1 gram evening dose). The AQNEURSA dosage in pediatric patients under 13 years was based on patient’s body weight [see Dosage and Administration (2.2)]. The approved dosage regimen is based on body weight and not age. Fifty-nine patients (98%) completed the study and received both placebo and AQNEURSA. One patient withdrew based on healthcare provider decision during AQNEURSA treatment.

    Of the 60 randomized patients (37 adults and 23 pediatric patients), 27 were female and 33 were male. The median age at treatment initiation was 25 years (range: 5 to 67 years). 90% of the patients were White, 3% Asian, and 7% Other. The majority of the patients (n=51, 85%) received miglustat treatment prior to randomization and during the trial.

    The primary efficacy outcome was assessed using a modified version of the Scale for Assessment and Rating of Ataxia (SARA), referred to as the functional SARA (fSARA). The SARA is a clinical assessment tool that assesses gait, stability, speech, and upper and lower limb coordination across 8 individual domains. The fSARA consists only of gait, sitting, stance, and speech disturbance domains of the original SARA with modifications to the scoring responses. Each domain was rescored from 0 to 4, where 0 is the best neurological status and 4 the worst, with a total score ranging from 0 to 16.

    The fSARA score was assessed at baseline, 6 weeks, 12 weeks (the end of Period I), 18 weeks, and 24 weeks (the end of Period II). The estimated mean fSARA total score was 5.1 when patients were treated with AQNEURSA and 5.6 when patients were treated with placebo. The estimated treatment difference for the fSARA total score was -0.4 (95% CI: -0.7, -0.2) (Table 4).

    Mean (SD)Mean (SD)Mean (SD)
    Table 4: Summary of fSARA Efficacy Results in Adult and Pediatric Patients with NPC (Trial 1)
    VariablefSARA Total Score
    Treatment Sequence 1:
    AQNEURSA - Placebo
    Treatment Sequence 2:
    Placebo - AQNEURSA
    CI = confidence interval; SD = standard deviation; SE = standard error.

    Baseline

    N=30

    N=30

     

    5.2 (3.0)

    6.3 (3.3)

    Period I

    N=29

    N=30

     

    4.5 (2.6)

    6.0 (3.4)

    Period II

    N=28

    Two patients did not have an assessment at the end of Period II (week 24).

    N=30

     

    5.1 (2.8)

    5.6 (3.1)

    Estimated Mean fSARA Score (SE) by Treatment

    AQNEURSA

    5.1 (0.1)

    Placebo

    5.6 (0.1)

    Treatment Difference (95% CI)

    -0.4 (-0.7, -0.2)

    Two-sided p-value <0.001

    Patients who received AQNEURSA in Period I followed by placebo in Period II (Treatment Sequence 1) showed a greater improvement in the fSARA score in Period I with a mean change from baseline of -0.5 (SD 1.2), compared to Period II with a mean change from baseline of 0 (1.5). Similarly, patients who received placebo in Period I followed by AQNEURSA in Period II (Treatment Sequence 2) experienced greater improvement in the fSARA score while receiving AQNEURSA in Period II with a mean change of -0.7 (0.9), compared to a mean change of -0.3 (0.9) in Period I.

    Figure 1: Mean (+/- standard error) Plot of the fSARA Total Score by Time and Treatment Sequence in Adult and Pediatric Patients with NPC (Trial 1)

    Mean (+/- Standard Error) Plot Of The Fsara Total Score By Time And Treatment Sequence (Image 02)

    Mean (+/- Standard Error) Plot Of The Fsara Total Score By Time And Treatment Sequence (Image 02)

    Results on the fSARA were supported by consistent results demonstrated on the original SARA.

14.2 Ataxia-Telangiectasia

The safety and efficacy of AQNEURSA for the treatment of ataxia in patients with A-T were evaluated in a randomized, double-blind, placebo-controlled, two-period crossover study that evaluated the efficacy of AQNEURSA in 73 patients (Trial 2; NCT06673056). To be eligible for the study, patients had to be aged 4 years or older with a confirmed diagnosis of A-T. Patients were required to have at least mild ataxia at baseline. Ataxia may be comprised of multiple signs and symptoms, including gait ataxia, truncal ataxia, oculomotor ataxia, and difficulties with balance, speech, and hand coordination.

Patients were assessed over a 2-week baseline period. Patients were then randomized in a 1:1 ratio to one of the two treatment sequences:

  • Treatment Sequence 1 (N=36): AQNEURSA in Treatment Period I, followed by immediate crossover to placebo in Treatment Period II
  • Treatment Sequence 2 (N=37): placebo in Treatment Period I, followed by immediate crossover to AQNEURSA in Treatment Period II.
  • AQNEURSA and placebo were administered orally with or without food for 12 weeks in each period.

    Patients weighing ≥35 kg received 4 gram per day (as 2 gram morning dose, 1 gram afternoon dose, and 1 gram evening dose). The AQNEURSA dosage in patients weighing under 35 kg was based on patient’s body weight [see Dosage and Administration (2.2)]. Seventy patients (96%) completed the study and received both placebo and AQNEURSA.

    Of the 73 randomized patients (26 adults and 47 pediatric patients), 38 were female and 35 were male. The median age at treatment initiation was 13 years (range: 4 to 50 years). 75% of the patients were White, 6% Asian, 1% Native Hawaiian or other Pacific Islander, 12% Not Reported, and 6% Other.

    Efficacy was demonstrated using a modified version of the SARA, referred to as the functional SARA (fSARA) [see Clinical Studies (14.1)].

    The fSARA score was assessed at baseline, 6 weeks, 12 weeks (the end of Period I), 18 weeks, and 24 weeks (the end of Period II). The Least Squares Mean fSARA total score was 7.2 when patients were treated with AQNEURSA and 7.8 when patients were treated with placebo. The Least Squares treatment effect for the fSARA total score was -0.6 (95% CI: -0.9, -0.2) (Table 5).

    Mean (SD)Mean (SD)Mean (SD)
    Table 5: Summary of fSARA Efficacy Results in Adult and Pediatric Patients with A-T (Trial 2)
    VariablefSARA Total Score
    Treatment Sequence 1:
    AQNEURSA - Placebo
    Treatment Sequence 2:
    Placebo - AQNEURSA
    CI = confidence interval; SD = standard deviation; SE = standard error.

    Baseline

    N=36

    N=37

     

    7.3 (2.6)

    8.5 (2.5)

    Period I

    N=34

    Two patients did not have an assessment at the end of Period I (week 12).

    N=37

     

    6.6 (2.8)

    8.5 (2.6)

    Period II

    N=35

    One patient did not have an assessment at the end of Period II (week 24).

    N=35

    Two patients did not have an assessment at the end of Period II (week 24).

     

    7.0 (3.1)

    7.8 (2.7)

    Least Squares Mean SARA Score (SE) by Treatment

    AQNEURSA

    7.2 (0.1)

    Placebo

    7.8 (0.1)

    Treatment Difference (95% CI)

    -0.6 (-0.9, -0.2)

    Two-sided p-value = 0.0013.

    Patients who received AQNEURSA in Period I followed by placebo in Period II (Treatment Sequence 1) showed a greater improvement in the fSARA score while receiving AQNEURSA in Period I with a mean change from baseline of -0.7 (SD 1.0), compared to Period II with a mean change from baseline of -0.2 (1.1). Patients who received placebo in Period I followed by AQNEURSA in Period II (Treatment Sequence 2) had a mean change of 0.0 (0.9) in Period I but experienced greater improvement in the fSARA score while receiving AQNEURSA in Period II with a mean change of -0.6 (1.3).

    Figure 2: Mean (+/- standard error) Plot of the fSARA Total Score by Time and Treatment Sequence in Adult and Pediatric Patients with A-T (Trial 2)

    Mean (+/- Standard Error) Plot Of The Sara Total Score By Time And Treatment Sequence (Image 03)

    Mean (+/- Standard Error) Plot Of The Sara Total Score By Time And Treatment Sequence (Image 03)

    Results on the fSARA were supported by consistent results demonstrated on the original SARA.

16 How Supplied/Storage And Handling

How Supplied

AQNEURSA (levacetylleucine) for oral suspension is supplied as white to off-white granules in a unit-dose multi-layer aluminum/polyethylene packet. Each packet contains 1.7 gram white to off-white granules, equivalent to 1 gram levacetylleucine.

NDC 83853-101-01: Carton containing 28 unit-dose packets

Storage and Handling

Store AQNEURSA at room temperature between 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

17 Patient Counseling Information

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Instructions for Use).

Embryo-Fetal Toxicity

AQNEURSA may cause embryo-fetal harm. Advise a pregnant female of the potential risk to the fetus. Advise a female of reproductive potential and caregiver to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Advise a female of reproductive potential to use effective contraception during treatment and for 7 days after the last dose if AQNEURSA is discontinued [see Use in Specific Populations (8.1, 8.3)].

Distributed by: IntraBio Inc., Austin TX 78701

AQNEURSA® is a registered trademark of IntraBio.

© 2026 IntraBio, Inc. All rights reserved.

Instructions For Use

AQNEURSA® [ak nur' sah]

(levacetylleucine)

for oral suspension

This Instructions for Use contains information on how to prepare and take or give AQNEURSA oral suspension. Read this Instructions for Use before you prepare and take or give the first dose of AQNEURSA oral suspension and each time you get a refill. There may be new information. This Instructions for Use does not take the place of talking to you or your child’s healthcare provider about your or your child’s medical condition or treatment.

Important Information You Need to Know Before Taking or Giving AQNEURSA Oral Suspension

  • Take or give AQNEURSA oral suspension exactly as instructed by your healthcare provider.
  • Take or give AQNEURSA oral suspension with or without food.
  • AQNEURSA oral suspension can be taken or given by mouth or through a gastrostomy tube (G-tube) feeding tube (French size 12 or larger).
  • Do not use hot liquid with AQNEURSA oral suspension.
  • For instructions on disposing of expired AQNEURSA packets or unused AQNEURSA oral suspension, see the end of this Instructions for Use.
  • Supplies Needed to Prepare and Take or Give AQNEURSA Oral Suspension

    Gather the following supplies on a clean flat surface:

    • the number of AQNEURSA packets needed for your prescribed dose
    • a clean spoon
    • a container
    • a measuring cup from your pharmacist
    • 40 mL of water, orange juice, almond milk, or yogurt
    • catheter tip syringe (if giving AQNEURSA oral suspension through G-tube)
    • Preparing AQNEURSA Oral Suspension

      Step 1: Wash and dry your hands.

      Step 2: Open and empty the entire contents of 1 AQNEURSA packet into a container with 40 mL of:

      • water, orange juice, almond milk, or yogurt (when taken by mouth), or
      • water only when given through a G-tube.
      • Do not use hot liquid.

      Empty The Entire Contents Of 1 Aqneursa Packet Into A Container With 40 mL Water (Image 04)

      Empty The Entire Contents Of 1 Aqneursa Packet Into A Container With 40 mL Water (Image 04)

      Step 3: Stir to form the suspension.

      Note:

      • Go to Step 4 for taking AQNEURSA oral suspension by mouth, or
      • Go to Step 6 for giving AQNEURSA oral suspension through a gastrostomy tube (G-tube).
      Stir To Form The Suspension (Image 05)

      Stir To Form The Suspension (Image 05)

      Taking AQNEURSA Oral Suspension by Mouth

      Step 4: Swallow AQNEURSA oral suspension right away (within 30 minutes).

      Throw away (dispose of) unused AQNEURSA oral suspension if not taken within 30 minutes.

      Swallow Aqneursa Oral Suspension Right Away (Image 06)

      Swallow Aqneursa Oral Suspension Right Away (Image 06)

      Step 5: If your prescribed dose requires 2 AQNEURSA packets, repeat Steps 1 through 4.

      Giving AQNEURSA Oral Suspension Through a Gastrostomy Tube (G-tube)

      • Give AQNEURSA oral suspension through a G-tube that is a French size of 12 or larger.
      • Follow Steps 1 through 3 to prepare AQNEURSA oral suspension.
      • Note: Only use 40 mL of water for preparing AQNEURSA oral suspension when given through G-tube.

      Step 6: Draw up the prepared AQNEURSA oral suspension into a catheter tip syringe.

      Draw Up The Prepared Aqneursa Oral Suspension Into A Catheter Tip Syringe (Image 07)

      Draw Up The Prepared Aqneursa Oral Suspension Into A Catheter Tip Syringe (Image 07)

      Step 7: Inject the AQNEURSA oral suspension through the G-tube right away.

      Throw away (dispose of) unused AQNEURSA oral suspension if not given right away.

      Inject The Aqneursa Oral Suspension Through The G-tube Right Away (Image 08)

      Inject The Aqneursa Oral Suspension Through The G-tube Right Away (Image 08)

      Step 8: Refill the syringe with an additional 20 mL water.

      Refill The Syringe With An Additional 20 mL Water (Image 09)

      Refill The Syringe With An Additional 20 mL Water (Image 09)

      Step 9: Flush the G-tube with water, until no remaining AQNEURSA oral suspension is seen in the syringe or G-tube.

      Flush The G-tube With Water (Image 10)

      Flush The G-tube With Water (Image 10)

      Step 10: If your prescribed dose requires 2 AQNEURSA packets, follow Steps 1 through 3 to prepare the AQNEURSA oral suspension, then repeat Steps 6 through 9.

      Storing AQNEURSA

      • Store AQNEURSA at room temperature between 68°F to 77°F (20°C to 25°C).
      • Keep AQNEURSA oral suspension and all medicines out of reach of children.
      • Disposing of Expired AQNEURSA Packets or Unused AQNEURSA Oral Suspension

        Throw away (dispose of) expired AQNEURSA packets or unused AQNEURSA oral suspension following the steps below:

        • Mix medicine with a substance such as dirt, cat litter, or used coffee grounds.
        • Place the mixture in a container such as a sealed plastic bag.
        • Throw away (dispose of) the container in your household trash.
        • Distributed by: IntraBio Inc., Austin, TX 78701

          AQNEURSA®is a registered trademark of IntraBio.

          This Instructions for Use has been approved by the U.S. Food and Drug Administration.

          Issued: 9/2026

* Please review the disclaimer below.